Hepatic glucagon action is essential for exercise-induced reversal of mouse fatty liver

Eric D. Berglund, Daniel G. Lustig, Richard A. Baheza, Clinton M. Hasenour, Robert S. Lee-Young, E. Patrick Donahue, Sara E. Lynes, Larry L. Swift, Maureen J. Charron, Bruce M. Damon, David H. Wasserman

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

OBJECTIVE - Exercise is an effective intervention to treat fatty liver. However, the mechanism(s) that underlie exercise-induced reductions in fatty liver are unclear. Here we tested the hypothesis that exercise requires hepatic glucagon action to reduce fatty liver. RESEARCH DESIGN AND METHODS - C57BL/6 mice were fed high-fat diet (HFD) and assessed using magnetic resonance, biochemical, and histological techniques to establish a timeline for fatty liver development over 20 weeks. Glucagon receptor null (gcgr -/-) and wild-type (gcgr +/+) littermate mice were subsequently fed HFD to provoke moderate fatty liver and then performed either 10 or 6 weeks of running wheel or treadmill exercise, respectively. RESULTS - Exercise reverses progression of HFD-induced fatty liver in gcgr +/+ mice. Remarkably, such changes are absent in gcgr -/- mice, thus confirming the hypothesis that exercise-stimulated hepatic glucagon receptor activation is critical to reduce HFD-induced fatty liver. CONCLUSIONS - These findings suggest that therapies that use antagonism of hepatic glucagon action to reduce blood glucose may interfere with the ability of exercise and perhaps other interventions to positively affect fatty liver.

Original languageEnglish (US)
Pages (from-to)2720-2729
Number of pages10
JournalDiabetes
Volume60
Issue number11
DOIs
StatePublished - Nov 2011

Fingerprint

Fatty Liver
Glucagon
Glucagon Receptors
Liver
High Fat Diet
Histological Techniques
Inbred C57BL Mouse
Running
Blood Glucose
Research Design
Magnetic Resonance Spectroscopy

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Berglund, E. D., Lustig, D. G., Baheza, R. A., Hasenour, C. M., Lee-Young, R. S., Donahue, E. P., ... Wasserman, D. H. (2011). Hepatic glucagon action is essential for exercise-induced reversal of mouse fatty liver. Diabetes, 60(11), 2720-2729. https://doi.org/10.2337/db11-0455

Hepatic glucagon action is essential for exercise-induced reversal of mouse fatty liver. / Berglund, Eric D.; Lustig, Daniel G.; Baheza, Richard A.; Hasenour, Clinton M.; Lee-Young, Robert S.; Donahue, E. Patrick; Lynes, Sara E.; Swift, Larry L.; Charron, Maureen J.; Damon, Bruce M.; Wasserman, David H.

In: Diabetes, Vol. 60, No. 11, 11.2011, p. 2720-2729.

Research output: Contribution to journalArticle

Berglund, ED, Lustig, DG, Baheza, RA, Hasenour, CM, Lee-Young, RS, Donahue, EP, Lynes, SE, Swift, LL, Charron, MJ, Damon, BM & Wasserman, DH 2011, 'Hepatic glucagon action is essential for exercise-induced reversal of mouse fatty liver', Diabetes, vol. 60, no. 11, pp. 2720-2729. https://doi.org/10.2337/db11-0455
Berglund ED, Lustig DG, Baheza RA, Hasenour CM, Lee-Young RS, Donahue EP et al. Hepatic glucagon action is essential for exercise-induced reversal of mouse fatty liver. Diabetes. 2011 Nov;60(11):2720-2729. https://doi.org/10.2337/db11-0455
Berglund, Eric D. ; Lustig, Daniel G. ; Baheza, Richard A. ; Hasenour, Clinton M. ; Lee-Young, Robert S. ; Donahue, E. Patrick ; Lynes, Sara E. ; Swift, Larry L. ; Charron, Maureen J. ; Damon, Bruce M. ; Wasserman, David H. / Hepatic glucagon action is essential for exercise-induced reversal of mouse fatty liver. In: Diabetes. 2011 ; Vol. 60, No. 11. pp. 2720-2729.
@article{d88ce31f2f8741f1a16810c5d347b01f,
title = "Hepatic glucagon action is essential for exercise-induced reversal of mouse fatty liver",
abstract = "OBJECTIVE - Exercise is an effective intervention to treat fatty liver. However, the mechanism(s) that underlie exercise-induced reductions in fatty liver are unclear. Here we tested the hypothesis that exercise requires hepatic glucagon action to reduce fatty liver. RESEARCH DESIGN AND METHODS - C57BL/6 mice were fed high-fat diet (HFD) and assessed using magnetic resonance, biochemical, and histological techniques to establish a timeline for fatty liver development over 20 weeks. Glucagon receptor null (gcgr -/-) and wild-type (gcgr +/+) littermate mice were subsequently fed HFD to provoke moderate fatty liver and then performed either 10 or 6 weeks of running wheel or treadmill exercise, respectively. RESULTS - Exercise reverses progression of HFD-induced fatty liver in gcgr +/+ mice. Remarkably, such changes are absent in gcgr -/- mice, thus confirming the hypothesis that exercise-stimulated hepatic glucagon receptor activation is critical to reduce HFD-induced fatty liver. CONCLUSIONS - These findings suggest that therapies that use antagonism of hepatic glucagon action to reduce blood glucose may interfere with the ability of exercise and perhaps other interventions to positively affect fatty liver.",
author = "Berglund, {Eric D.} and Lustig, {Daniel G.} and Baheza, {Richard A.} and Hasenour, {Clinton M.} and Lee-Young, {Robert S.} and Donahue, {E. Patrick} and Lynes, {Sara E.} and Swift, {Larry L.} and Charron, {Maureen J.} and Damon, {Bruce M.} and Wasserman, {David H.}",
year = "2011",
month = "11",
doi = "10.2337/db11-0455",
language = "English (US)",
volume = "60",
pages = "2720--2729",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "11",

}

TY - JOUR

T1 - Hepatic glucagon action is essential for exercise-induced reversal of mouse fatty liver

AU - Berglund, Eric D.

AU - Lustig, Daniel G.

AU - Baheza, Richard A.

AU - Hasenour, Clinton M.

AU - Lee-Young, Robert S.

AU - Donahue, E. Patrick

AU - Lynes, Sara E.

AU - Swift, Larry L.

AU - Charron, Maureen J.

AU - Damon, Bruce M.

AU - Wasserman, David H.

PY - 2011/11

Y1 - 2011/11

N2 - OBJECTIVE - Exercise is an effective intervention to treat fatty liver. However, the mechanism(s) that underlie exercise-induced reductions in fatty liver are unclear. Here we tested the hypothesis that exercise requires hepatic glucagon action to reduce fatty liver. RESEARCH DESIGN AND METHODS - C57BL/6 mice were fed high-fat diet (HFD) and assessed using magnetic resonance, biochemical, and histological techniques to establish a timeline for fatty liver development over 20 weeks. Glucagon receptor null (gcgr -/-) and wild-type (gcgr +/+) littermate mice were subsequently fed HFD to provoke moderate fatty liver and then performed either 10 or 6 weeks of running wheel or treadmill exercise, respectively. RESULTS - Exercise reverses progression of HFD-induced fatty liver in gcgr +/+ mice. Remarkably, such changes are absent in gcgr -/- mice, thus confirming the hypothesis that exercise-stimulated hepatic glucagon receptor activation is critical to reduce HFD-induced fatty liver. CONCLUSIONS - These findings suggest that therapies that use antagonism of hepatic glucagon action to reduce blood glucose may interfere with the ability of exercise and perhaps other interventions to positively affect fatty liver.

AB - OBJECTIVE - Exercise is an effective intervention to treat fatty liver. However, the mechanism(s) that underlie exercise-induced reductions in fatty liver are unclear. Here we tested the hypothesis that exercise requires hepatic glucagon action to reduce fatty liver. RESEARCH DESIGN AND METHODS - C57BL/6 mice were fed high-fat diet (HFD) and assessed using magnetic resonance, biochemical, and histological techniques to establish a timeline for fatty liver development over 20 weeks. Glucagon receptor null (gcgr -/-) and wild-type (gcgr +/+) littermate mice were subsequently fed HFD to provoke moderate fatty liver and then performed either 10 or 6 weeks of running wheel or treadmill exercise, respectively. RESULTS - Exercise reverses progression of HFD-induced fatty liver in gcgr +/+ mice. Remarkably, such changes are absent in gcgr -/- mice, thus confirming the hypothesis that exercise-stimulated hepatic glucagon receptor activation is critical to reduce HFD-induced fatty liver. CONCLUSIONS - These findings suggest that therapies that use antagonism of hepatic glucagon action to reduce blood glucose may interfere with the ability of exercise and perhaps other interventions to positively affect fatty liver.

UR - http://www.scopus.com/inward/record.url?scp=80755148711&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80755148711&partnerID=8YFLogxK

U2 - 10.2337/db11-0455

DO - 10.2337/db11-0455

M3 - Article

C2 - 21885872

AN - SCOPUS:80755148711

VL - 60

SP - 2720

EP - 2729

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 11

ER -